Clinical trials: Diabetes Type 1
Type 1 Diabetes
Effect of Liraglutide on Automated Closed-loop Glucose Control in Type 1 Diabetes
"Closed loop artificial pancreas" systems have been under development for the control of blood sugars in those living with diabetes.
- Trial name
- NCT01856790
- Testing
- ePID closed loop system, liraglutide
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Jennifer Sherr
Type 1 Diabetes Mellitus
Anti-inflammatory Therapy With Anakinra in Newly Diagnosed Type 1 Diabetes
The purpose of this study is to determine whether control of inflammatory pathways mediated by IL-1 beta using the IL-1 receptor antagonist anakinra will yield measurable decreases in expression of genes that are otherwise…
- Trial name
- NCT00645840
- Testing
- Anakinra
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Texas Southwestern Medical Center
Islet Transplantation in Diabetes Mellitus Type 1
Study to Assess Efficacy & Safety of Reparixin in Pancreatic Islet Transplantation
The objective of this clinical trial was: to assess whether Reparixin leads to improved transplant outcome as measured by glycaemic control following intra-hepatic infusion of pancreatic islets in patients with Type 1 diabetes…
- Trial name
- REP0211 (NCT01817959)
- Testing
- Reparixin
- Where
- 9 sites in United States, Czechia and 3 more
- Volunteers
- 51 people
- Sponsor
- Dompé Farmaceutici S.p.A
Type 1 Diabetes Mellitus
Physiologic Response to Glucagon at Varying Insulin Levels
The purpose of this research study is to test how different levels of insulin block the effect of glucagon. Insulin is a hormone that lowers blood glucose. Glucagon raises blood glucose.
- Trial name
- NCT01483651
- Testing
- Glucagon, Insulin
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Legacy Health System
Diabetes Mellitus, Type 1
SWITCH - Sensing With Insulin Pump Therapy to Control HbA1c
The primary objective of this study is to evaluate whether the patients with Type 1 diabetes mellitus in sub-optimal glycemic control can achieve better glycemic control by using the Medtronic MiniMed Paradigm® REAL-Time Pump…
- Trial name
- SWITCH (NCT00598663)
- Testing
- insulin pump with continuous glucose sensing (Paradigm Real-Time Insulin Pump System), insulin pump and blinded continuous glucose sensing (Paradigm Real-Time insulin pump)
- Where
- 8 sites in Austria, Denmark and 5 more
- Volunteers
- 153 people, healthy volunteers welcome
- Sponsor
- Medtronic MiniMed, Inc.
Type 1 Diabetes Mellitus
Afrezza Safety and Pharmacokinetics Study in Pediatric Patients
Primary Objective: -To assess the safety and tolerability of Afrezza in children ages 4 to 17 years with type 1 diabetes mellitus (T1DM).
- Trial name
- NCT02527265
- Testing
- Afrezza
- Where
- 13 sites in United States
- Volunteers
- 30 people
- Sponsor
- Mannkind Corporation
Type 1 Diabetes
Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6
A single-arm, multi-center, clinical study to assess the safety profile of the Tandem t:slim X2 with Control-IQ system in children with T1D aged 2-6 years old under free living condition
- Trial name
- NCT04084171
- Testing
- Tandem t:slim X2 with Control-IQ Technology + Dexcom G6
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- University of Virginia
Eating Disorders, Type 1 Diabetes
Eating Disorder Prevention Program for Women With T1D
This study aims to test the effectiveness of an evidence-based eating- disorder prevention program specifically targeted for individuals with Type 1 Diabetes (T1D) compared to an educational control group.
- Trial name
- NCT05264376
- Testing
- Diabetes Body Project, Educational Control
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Stanford University
Type 1 Diabetes Mellitus
Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes
The purpose of this study is to determine if adding dapagliflozin to insulin is a safe and effective therapy to improve glycemic control in patients with type 1 diabetes.
- Trial name
- DEPICT 2 (NCT02460978)
- Testing
- Dapagliflozin
- Where
- 136 sites in United States, Argentina and 11 more
- Volunteers
- 815 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Effectiveness and Safety Study of the Abbott Sensor Based Glucose Monitoring Systems
The purpose of the study is to evaluate the safety and effectiveness of the Abbott Sensor Based Glucose Monitoring System Personal (System-P) and Abbott Sensor Based Glucose Monitoring System Professional (System-Pro) when used…
- Trial name
- NCT02283411
- Testing
- Abbott Sensor Based Glucose Monitoring System
- Where
- 6 sites in United States
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- Abbott Diabetes Care
Diabetes Mellitus, Type 1
Effect of Methyldopa on MHC Class II Antigen Presentation in Type 1 Diabetes
Type 1 Diabetes is an autoimmune condition in which segments of the immune system cause the destruction of insulin producing cells in the pancreas, leaving individuals with an impaired ability to control blood glucose levels.
- Trial name
- NCT01883804
- Testing
- Methyldopa
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Colorado, Denver
Type 2 Diabetes Mellitus
A Multiple-ascending-dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes Mellitus
A Phase 1/2, multiple dose study with 6 cohorts of ascending doses designed to evaluate the efficacy, safety and pharmacokinetics (PK) of MEDI0382 in participants with Type 2 Diabetes Mellitus (T2DM).
- Trial name
- NCT02548585
- Testing
- MEDI0382
- Where
- 11 sites in Germany
- Volunteers
- 113 people
- Sponsor
- MedImmune LLC
Type 1 Diabetes Mellitus
Cognitive Adaptations to Reduce Emotional Stress Associated With Type 1 Diabetes
The purpose of this study is to evaluate a new intervention (CARES: Cognitive Adaptations to Reduce Emotional Stress Associated with Type 1 Diabetes) designed to reduce caregiver depressive symptoms in families of children with…
- Trial name
- CARES (NCT03698708)
- Testing
- CARES Intervention
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Kansas Medical Center
Type 1 Diabetes Mellitus, Dyslipidemia
Clinical Trial of Zocor (Simvastatin) and Vytorin (Ezetimibe/Simvastatin) in Adolescents With Type 1 Diabetes
The purpose of the study is to establish the safety of ezetimibe/simvastatin and simvastatin in adolescents with Type 1 Diabetes and to determine the amount of decrease in LDL-cholesterol.The study hypothesizes that simvastatin…
- Trial name
- NCT00477204
- Testing
- Simvastatin, Ezetimibe/Simvastatin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Colorado, Denver
Diabetes, Type I
Efficacy & Safety of Inhaled Insulin in Type 1 Diabetes
To determine the safety and efficacy of inhaled insulin in the treatment of type 1 diabetes
- Trial name
- NCT00308308
- Testing
- Technosphere Insulin, Active comparator
- Where
- 129 sites in United States, Argentina and 8 more
- Volunteers
- 589 people, healthy volunteers welcome
- Sponsor
- Mannkind Corporation
Hypoglycemia Unawareness, Type 1 Diabetes
Glucose Counterregulation in Long Standing Type 1 Diabetes
Enrollment for this study is complete. This study is designed to determine if use of a real-time continuous glucose monitor (RT-CGM) can reverse defective Glucose counter regulation and hypoglycemia unawareness in long standing…
- Conditions
- Hypoglycemia Unawareness, Type 1 Diabetes, Healthy
- Trial name
- NCT01474889
- Testing
- RT-CGM
- Where
- 3 sites in United States
- Volunteers
- 37 people
- Sponsor
- University of Pennsylvania
Type 1 Diabetes
Two Way Crossover Closed Loop Study Insulin vs Insulin and Pramlintide
The purpose of this study is to test how well a new investigational closed loop system manages your blood sugar with the ability to deliver insulin and pramlintide.
- Trial name
- NCT06422325
- Testing
- MPC closed-loop system in insulin only mode, MPC closed-loop system in insulin/pramlintide mode
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Oregon Health and Science University
Gastroparesis
Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis
GSK962040 is a novel small molecule motilin agonist. The Phase I studies (MOT107043 and MOT109681) demonstrated that single doses of GSK962040 up to 150 mg and repeat dosing of up to 125 mg/day for 14 days were well tolerated…
- Trial name
- NCT01262898
- Testing
- GSK962040 (5 mg tablet), GSK962040 (25 mg tablet), GSK962040 (125 mg tablet)
- Where
- 22 sites in United States, Australia and 4 more
- Volunteers
- 79 people
- Sponsor
- GlaxoSmithKline
Type 1 Diabetes
Selecting Insulin Analogs for Closed-Loop Control Using Multiplex Pharmacokinetic Profiling
The investigators are doing this research study to compare the pharmacokinetics (PK) (rate of absorption) of insulin lispro (Humalog), insulin aspart (Novolog), and insulin glulisine (Apidra) within individual subjects.
- Trial name
- NCT01684943
- Testing
- Multiplex pharmacokinetic profiling, Continuous insulin monitoring
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Massachusetts General Hospital
Type 1 Diabetes
Accelerometer Use in the Prevention of Exercise-Associated Hypoglycemia in Type 1 Diabetes: Outpatient Exercise Protocol
Manually suspending an insulin pump at the beginning of aerobic exercise reduces the risk of exercise-associated hypoglycemia (low blood sugar) in patients with type 1 diabetes (T1D).
- Trial name
- NCT02047643
- Testing
- Computer algorithm to initiate pump suspension
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Stanford University